Incidence and Risk Factors of Active Tuberculosis Among Hospitalized Patients with Latent Tuberculosis Infection in China: A Cohort Study

References

• Bagcchi S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe. 2023;4(1):e20. doi:10.1016/S2666-5247(22)00359-7
   PubMedGoogle Scholar
• World Health organization. Implementing the end TB strategy: the essentials, 2022 update. World Health Organization; 2022. Available from: https://www.who.int/publications/i/item/9789240065093. Accessed March 7, 2024.
   Google Scholar
• World Health organization. The end TB strategy. World Health organization; 2015. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19. Accessed March 7, 2024.
   Google Scholar
• Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–138. doi:10.1093/oxfordjournals.aje.a121593
   PubMed Web of Science ®Google Scholar
• World Health organization. Guidelines on the Management of Latent Tuberculosis Infection. World Health organization; 2015. Available from: https://www.who.int/publications/i/item/9789241548908. Accessed March 7, 2024.
   Google Scholar
• Gao L, Zhang H. Expert consensus on the estimation of the national burden on latent tuberculosis infection. Chin J Antituberculosis. 2022;44(1):4–8. doi:10.19982/j.issn.1000-6621.20210662
   Google Scholar
• Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–2135. doi:10.1056/NEJMra1405427
   PubMed Web of Science ®Google Scholar
• Long W, Cai F, Wang X, et al. High risk of activation of latent tuberculosis infection in rheumatic disease patients. Infect Dis. 2020;52(2):80–86. doi:10.1080/23744235.2019.1682187
   PubMed Web of Science ®Google Scholar
• Gao L, Li X, Liu J, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017;17(10):1053–1061. doi:10.1016/S1473-3099(17)30402-4
   PubMed Web of Science ®Google Scholar
• People’s Republic of China state health and Family Planning Commission. Diagnostic criteria for tuberculosis (WS 288—2017). Electr J Emerg Infect Dis. 2018;3(01):59–61. doi:10.19871/j.cnki.xfcrbzz.2018.01.017
   Google Scholar
• People’s Republic of China state health and Family Planning Commission. Tuberculosis classification (WS196—2017). Electr J Emerg Infect Dis. 2018;3(3):191–192. doi:10.19871/j.cnki.xfcrbzz.2018.03.018
   Google Scholar
• Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549. doi:10.1136/bmj.m549
   PubMedGoogle Scholar
• Shah M, Dorman SE, Solomon CG. Latent Tuberculosis Infection. N Engl J Med. 2021;385(24):2271–2280. doi:10.1056/NEJMcp2108501
   PubMed Web of Science ®Google Scholar
• Ai JW, Ruan QL, Liu QH, et al. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2):e10. doi:10.1038/emi.2016.10
   PubMedGoogle Scholar
• Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis. 2008;12(12):1352–1364.
   PubMed Web of Science ®Google Scholar
• Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–247. doi:10.1038/nri.2017.1
   PubMed Web of Science ®Google Scholar
• Xie Y, Xie J, Meijer AH, et al. Glucocorticoid-Induced Exacerbation of Mycobacterial Infection Is Associated with a Reduced Phagocytic Capacity of Macrophages. Front Immunol. 2021;12:618569. doi:10.3389/fimmu.2021.618569
   PubMed Web of Science ®Google Scholar
• Zhang L, Zou X, Jiang N, et al. Incidence and risk factors of tuberculosis in systemic lupus erythematosus patients: a multi-center prospective cohort study. Front Immunol. 2023;14:1157157. doi:10.3389/fimmu.2023.1157157
   PubMed Web of Science ®Google Scholar
• Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70(7):677–682. doi:10.1136/thoraxjnl-2014-206470
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Capone A, et al. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019;18(5):415–425. doi:10.1080/14740338.2019.1612872
   PubMed Web of Science ®Google Scholar
• Breedveld F, Dayer J. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59(11):841–849. doi:10.1136/ard.59.11.841
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Dougados M. Leflunomide for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2003;4(6):987–997. doi:10.1517/14656566.4.6.987
   PubMed Web of Science ®Google Scholar
• Kang Y-J, Park H, Park S-B, et al. Combined analysis of whole blood interferon gamma release assay and complete blood count analysis for rapid discrimination of active tuberculosis and latent tuberculosis infection. J Clin Tuberc Other Mycobact Dis. 2021;24:100253. doi:10.1016/j.jctube.2021.100253
   PubMedGoogle Scholar
• VanValkenburg A, Kaipilyawar V, Sarkar S, et al. Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis. Front Immunol. 2022;13:1011166. doi:10.3389/fimmu.2022.1011166
   PubMed Web of Science ®Google Scholar
• Lee SW, Kang YA, Yoon YS, et al. The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci. 2006;21(6):1028–1032. doi:10.3346/jkms.2006.21.6.1028
   PubMed Web of Science ®Google Scholar
• Kang WL, Wang GR, Wu MY, et al. Interferon-gamma release assay is not appropriate for the diagnosis of active tuberculosis in high-burden tuberculosis settings: a retrospective multicenter investigation. Chin Med J. 2018;131(3):268–275. doi:10.4103/0366-6999.223860
   PubMed Web of Science ®Google Scholar
• Herrmann JL, Belloy M, Porcher R, et al. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS One. 2009;4(1):e4130. doi:10.1371/journal.pone.0004130
   PubMed Web of Science ®Google Scholar
• Ledesma JR, Ma J, Zheng P, et al. Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis. BMC Infect Dis. 2021;21(1):467. doi:10.1186/s12879-021-06141-4
   PubMed Web of Science ®Google Scholar